Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 5
2005 1
2006 1
2007 5
2008 4
2011 1
2012 1
2013 2
2014 1
2016 1
2017 4
2018 1
2019 4
2020 2
2021 1
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Safety Profile of Bremelanotide Across the Clinical Development Program.
Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R, Lucas J, Simon JA. Clayton AH, et al. J Womens Health (Larchmt). 2022 Feb;31(2):171-182. doi: 10.1089/jwh.2021.0191. J Womens Health (Larchmt). 2022. PMID: 35147466 Clinical Trial.
Methods: Review of bremelanotide's safety profile from the clinical development program (phases 1 through 3). ...Conclusions: The AEs associated with bremelanotide are mostly mild to moderate. Although not deemed clinically important, bremelanotide should be …
Methods: Review of bremelanotide's safety profile from the clinical development program (phases 1 through 3). ...Conclusions: The AEs …
Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.
Mayer D, Lynch SE. Mayer D, et al. Ann Pharmacother. 2020 Jul;54(7):684-690. doi: 10.1177/1060028019899152. Epub 2020 Jan 1. Ann Pharmacother. 2020. PMID: 31893927
Data Sources: Literature search of Medline, SCOPUS, and EMBASE was performed using the search terms bremelanotide, bremelanotide injection, Vyleesi, and melanocortin 4 receptor agonist between January 1, 1996, and December 15, 2019. ...Bremelanotide's place i …
Data Sources: Literature search of Medline, SCOPUS, and EMBASE was performed using the search terms bremelanotide, bremelanotide …
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.
Cipriani S, Alfaroli C, Maseroli E, Vignozzi L. Cipriani S, et al. Expert Opin Pharmacother. 2023 Jan;24(1):15-21. doi: 10.1080/14656566.2022.2132144. Epub 2022 Oct 18. Expert Opin Pharmacother. 2023. PMID: 36242769 Review.
AREAS COVERED: Hereby we summarize bremelanotide's proposed mechanism of action, pharmacokinetics, efficacy and safety data derived from clinical trials. A literature search of peer-reviewed publications on the current evidence on the pharmacotherapy with bremelanotide …
AREAS COVERED: Hereby we summarize bremelanotide's proposed mechanism of action, pharmacokinetics, efficacy and safety data derived f …
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Simon JA, Kingsberg SA, Portman D, Jordan R, Lucas J, Sadiq A, Krop J, Clayton AH. Simon JA, et al. J Womens Health (Larchmt). 2022 Mar;31(3):391-400. doi: 10.1089/jwh.2021.0225. Epub 2022 Feb 25. J Womens Health (Larchmt). 2022. PMID: 35230162 Clinical Trial.
This report investigates efficacy of bremelanotide versus placebo according to prespecified subgroups (age, weight, body mass index [BMI], and bioavailable testosterone) in the RECONNECT studies. Materials and Methods: Patients self-administered bremelanotide 1.75 m …
This report investigates efficacy of bremelanotide versus placebo according to prespecified subgroups (age, weight, body mass index [ …
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Kingsberg SA, et al. Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500. Obstet Gynecol. 2019. PMID: 31599840 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the safety and efficacy of bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder. ...Patients taking bremelanotide experienced more nausea, flushing, and headache (10% or more in both studies) compared w …
OBJECTIVE: To evaluate the safety and efficacy of bremelanotide for the treatment of premenopausal women with hypoactive sexual desir …
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
Althof S, Derogatis LR, Greenberg S, Clayton AH, Jordan R, Lucas J, Spana C. Althof S, et al. J Sex Med. 2019 Aug;16(8):1226-1235. doi: 10.1016/j.jsxm.2019.05.012. Epub 2019 Jul 2. J Sex Med. 2019. PMID: 31277966 Clinical Trial.
CLINICAL IMPLICATIONS: These responder definitions were subsequently used in the bremelanotide phase 3 registration studies (RECONNECT) that evaluated the safety and efficacy of the bremelanotide 1.75 mg subcutaneous dose in premenopausal women with HSDD. ...Respond …
CLINICAL IMPLICATIONS: These responder definitions were subsequently used in the bremelanotide phase 3 registration studies (RECONNEC …
Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.
Spana C, Jordan R, Fischkoff S. Spana C, et al. Diabetes Obes Metab. 2022 Jun;24(6):1084-1093. doi: 10.1111/dom.14672. Epub 2022 Mar 15. Diabetes Obes Metab. 2022. PMID: 35170192 Free PMC article.
Study A matched subjects 1:1 to receive subcutaneous placebo or bremelanotide three times daily for days 1-15. Study B was a crossover trial with six distinct treatment sequences consisting of three 4-day treatment periods, investigating once-a-day and twice-a-day exposure …
Study A matched subjects 1:1 to receive subcutaneous placebo or bremelanotide three times daily for days 1-15. Study B was a crossove …
PT-141 Palatin.
Hedlund P. Hedlund P. Curr Opin Investig Drugs. 2004 Apr;5(4):456-62. Curr Opin Investig Drugs. 2004. PMID: 15134289 Review.
Pharmaceutical aphrodisia.
Bridges TM. Bridges TM. Curr Top Med Chem. 2007;7(11):1152. doi: 10.2174/156802607780906582. Curr Top Med Chem. 2007. PMID: 17722370 No abstract available.
39 results